anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To improve the degree of freedom for formation of a system by connecting via a transmission line, a filing device which stores plural pieces of medical image information and reads out a stored image as necessary and at the same time by star LAN connecting the plural image filing devices to the medical diagnostic devices. CONSTITUTION:The medical diagnostic devices 10A1-10An such as the CR, CT and MR devices, etc., which output the medical image information on the diagnosis are star LAN connected to the image filing devices 10A-10G via the circuit of low capacity. The medical image information inputted by the devices 10A1-10An are stored in the devices 10A-10G. At the same time, the devices 10A-10G having the star LAN connection to the plural devices 10A1-10An are connected to each other via a transmission line. Thus even such medical image information stored in other image filing devices having no direct connection to the devices 10A1-10An are also retrieved and displayed via the medical diagnostic devices. Thus the degree of freedom for formation of a medical image information system is improved together with the economy. Furthermore the transfer processing ability is improved for the image information.
An on-body sensor system (30) comprises at least two skin-engaging units (32, 34) for coupling signals into and out of the body, wherein one of said units is for placement at a known location. One unit applies an electrical signal to the body and the other unit senses it at a remote location. By analyzing the sensed signals using a set of predetermined body transmission parameters, the position of one of the skin engaging units may be determined. This allows for accurate placement of one of the units, for example to allow more accurate monitoring of a physiological parameter using that unit. The body transmission parameters can vary over time, and once the engaging units are put in place, their positions are stable. The system therefore also comprises the function of recalibrating the transmission parameters using at least one known stable set of initial positions of the joining unit. The recalibration comprises a process of recalculating parameters based on the known positions. These can then be stored and used for determining the position of one of the skin-engaging units having the movable position in the future, for example in case of a replacement or replacement of the skin-engaging unit.
Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including levomilnacipran. In many cases, hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. Levomilnacipran should be discontinued in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.
Roux-en-Y gastric bypass (RYGB); the stomach is divided with staplers to create a small gastric pouch, while the jejunum is divided 30 to 50 cm distal to the ligament of Treitz. The distal limb is then anastomosed to the small gastric pouch and a jejunojejunostomy is performed 50 to 150 cm distal from the gastrojejunostomy.
This study was conducted in patients with acute myocardial infarction who undergo emergency PCI in Chinese PLA General Hospital. The patients were randomly divided into two groups: the adequate hydration group guided by Vigileo and control group. For the adequate hydration group guided by Vigileo, Vigileo equipment is used to perform hemodynamic monitoring through the femoral or radial arteries to obtain relevant hemodynamic parameters (CO, SV, SVV), and the fluid-rehydration velocity of normal saline is adjusted according to the hemodynamic parameters, and the hydration also lasts 24 hours after operation. For the control group, the routine hydration regimen is adopted, perioperative saline ≤500 ml hydration. The changes of renal function (serum creatinine, serum cystatin), symptoms and signs of cardiac insufficiency during perioperative period and cardiac objective indexes are observed. The incidence of postoperative acute pulmonary edema is recorded, and the major cardiovascular events and hemodialysis events are followed up for 6 months. By comparing the perioperative indexes of heart and kidney function between the intervention group and the control group, the preventive effect of adequate hydration guided by Vigileo on contrast induced nephropathy after PCI was clarified.
Generalized anxiety disorder (GAD) affects nearly 6.8 million adults in the United States. GAD is diagnosed when a person spends at least 6 months excessively worrying over everyday problems to the point that carrying out normal life becomes difficult. People with GAD face each day with intense anxiety and tension and are unable to alleviate their worries. Physical symptoms of GAD include muscle aches, nausea, sweating, exhaustion, irritability, frequent urination, shaking, and hot flashes. People with GAD often experience other anxiety disorders, depression, or substance abuse, all of which can worsen symptoms of GAD. This makes early and appropriate treatment for GAD important. Current treatments for GAD include medication and/or types of psychotherapy. This study will assess whether adding cognitive behavioral therapy (CBT) to the antidepressant escitalopram is effective in reducing anxiety in older adults with GAD.

Participation in this double-blind study will last up to 13 months. Participants will be asked to stop any current treatments for anxiety or depression for the duration of the study. Participants will begin taking one pill of the medication escitalopram daily for 12 weeks. Dosage will be increased to two pills each day if symptoms do not improve within 4 weeks. After 12 weeks, all participants will continue taking escitalopram for an additional 16 weeks. In addition, some participants will be randomly assigned to receive 16 weekly sessions of CBT, lasting 1 hour each. CBT sessions will involve learning relaxation techniques and other skills to manage anxiety and completing 30-minute at-home practice assignments each day. A family member will accompany participants to the first four CBT sessions. All participants will be asked to provide information for a close contact, who will be interviewed at baseline, Month 3, and Month 7 about how the participant's anxiety is affecting his or her relationships.

After the 16-week period, participants will again be randomly assigned to receive either continued escitalopram or a placebo for an additional 28 weeks. Participants assigned to the placebo will be gradually tapered off escitalopram over a 6-week period. Participants who were receiving CBT will receive three more sessions. Throughout the study, participants will be asked to complete various assessments, including questionnaires, memory and thinking tests, and attention evaluations. Blood samples will be taken at Weeks 2 and 8, and saliva samples will be taken at baseline and Weeks 12, 28, and 56.
BACKGROUND: We aimed to investigate effect of radiotherapy (RT) applications with different dose rates on cytogenetic damages, which focused on micronucleus (MN) formation, and evaluate how this damage varies by cisplatin in rats receiving head-neck RT.
MATERIAL AND METHODS: Thirty-six Sprague Dawley rats were divided into five groups. The first and second groups were irradiated at a dose rate of 300 monitor unit/minute (MU/min) and 600 MU/min, respectively. The third group was irradiated at a dose rate of 300 MU/min and given cisplatin. The fourth group was irradiated at a dose rate of 600 MU/min and given cisplatin. The fifth group received neither irradiation nor cisplatin (control group). One thousand polychromatic erythrocytes were scored, and MN frequency in polychromatic erythrocytes was determined for each rat.
RESULTS: There was a significant difference among five groups in terms of the number of MN (p: 0.001). The number of MN was significantly higher in the 600 MU/min + cisplatin group (fourth group) compared to the control group [9.5 (1.0-23.0) vs. 1.5 (1.0-2.0), respectively]. It was also significantly higher in 600 MU/min + cisplatin group (fourth group) compared to 300 MU/min group (first group) [9.5 (1.0-23.0) vs. 2.0 (1.0-3.0), respectively]. On the other hand, there was no significant difference among other groups.
CONCLUSIONS: Our findings suggest that RT given at a higher dose rate causes more cytogenetic damage, and this damage is increased by concurrent administration of cisplatin.
FIELD: medicine; pharmaceutics. ^ SUBSTANCE: preparation of an opioid for anaesthesia in the form of a medical product for inhalation which represents an admixture of free phentranyl and phentranyl bagged in liposomes in the ratio from 1:2 to 6:1 is offered, it is preferable from 1:2 to 1:4, it is more preferable in concentration from, approximately, 40% of free phentranyl to approximately 60% of phentranyl, bagged in liposomes, with the general concentration of an opioid about 250-1500 and a corresponding way of anaesthesia. The invention provides dosage of a preparative form only at realisation of the conscious effort by the patient. It allows the patient to limit medical product reception independently. ^ EFFECT: possibility to avoid toxicity at anaesthesia achievement. ^ 11 cl, 22 dwg
Despite the success of Tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML), leukemic stem cells (LSCs) persist, contributing to relapse and resistance. CML Mesenchymal Stromal Cells (MSCs) help in LSC maintenance and protection from TKIs. However, the limited passage and self-differentiation abilities of primary CML MSCs hinder extensive research. To overcome this, we generated and characterized an immortalised CML patient-derived MSC (iCML MSC) line and assessed its role in LSC maintenance. We also compared the immunophenotype and differentiation potential between primary CML MSCs at diagnosis, post-treatment, and with normal bone marrow MSCs. Notably, CML MSCs exhibited enhanced chondrogenic differentiation potential compared to normal MSCs. The iCML MSC line retained the trilineage differentiation potential and was genetically stable, enabling long-term investigations. Functional studies demonstrated that iCML MSCs protected CML CD34+ cells from imatinib-induced apoptosis, recapitulating the bone marrow microenvironment-mediated resistance observed in patients. iCML MSC-conditioned media enabled CML CD34+ and AML blast cells to proliferate rapidly, with no impact on healthy donor CD34+ cells. Gene expression profiling revealed dysregulated genes associated with calcium metabolism in CML CD34+ cells cocultured with iCML MSCs, providing insights into potential therapeutic targets. Further, cytokine profiling revealed that the primary CML MSC lines abundantly secreted 25 cytokines involved in immune regulation, supporting the hypothesis that CML MSCs create an immune modulatory microenvironment that promotes growth and protects against TKIs. Our study establishes the utility of iCML MSCs as a valuable model to investigate leukemic-stromal interactions and study candidate genes involved in mediating TKI resistance in CML LSCs.
FIELD: medicine, immunology. SUBSTANCE: method of preparing immunoglobulin preparation involves salt extraction of human blood serum alcoholic extract, its purification to remove lipoproteins followed by isolation of the end product, addition of glucose-containing stabilizing agent and sterilizing filtration. Immunoglobulins are isolated by precipitation with alcohol. Mixture of glycine and glucose taken in the ratio (1-1.5):1 is used as a stabilizing agent. Immunoglobulin solution is treated with glass sorbent and at the stage of isolation of the end product flowing-zonal centrifugation is carried out. Before sterilizing filtration solution is passed through the porous glass filter. EFFECT: increased yield, decreased cost of preparation. 2 ex
1424186 α-Carboxy penicillins BEECHAM GROUP Ltd 8 Sept 1972 [8 Oct 1971] 46929/71 Heading C2C Novel α-carboxy penicillins of Formula (I) and their salts and esters, wherein R is a fully saturated heterooyclic radical or a fully saturated cycloalkyl radical are prepared by N- acylating 6-aminopenicillanic acid or a salt, ester or silyl derivative thereof, with an N- acylating reactive derivative of an acid of Formula (VII) wherein R is as defined above and X is a hydroxy group or the radical -OR<SP>2</SP> in which R<SP>2</SP> is an alkyl, aryl, benzyl or substituted benzyl group, and when X is -OR<SP>2</SP>, subsequently converting R<SP>2</SP> to hydrogen. The group R is preferably a C 3-8  cycloalkyl group or a monocyclic heterocyclic group having 5-7 ring atoms and one or more identical or different hetero atoms, for example groups of the following formulae wherein Z is O, S, in which R 1  is H, C 1-6  alkyl, aryl, aralkyl or aryloxy carbonyl. Reactive derivatives of the acid (VII) may be the acid halide, azide, anhydride, mixed anhydride or the reactive intermediate formed from the acid and a carbodiimide or carbonyldiimidazole. Esters of the compounds (I) include those wherein one or both of the carboxyl groups (i.e. the α-COOH and the 4-COOH group) are esterified. Benzyl hydrogen cycloalkylmalonates wherein the cycloalkyl group is cyclopropyl, cyclopentyl, cyclohexyl, and cycloheptyl are prepared by converting an appropriate cycloalkylmalonic acid to the acid chloride and reacting the latter with benzyl alcohol. The benzyl hydrogen cycloalkylmalonates are then converted to their acid chlorides by reaction with thionyl chloride. Benzyl hydrogen 2-tetrahydropyranylmalonate is produced by treating 2-tetrahydropyranylmalonic acid with an ethereal solution ofphenyldiazomethane prepared by reacting N-nitroso- N-benzyltoluene-4-sulphonamide and sodium methoxide in methanol and ether. Tetrahydrothiophen - 1,1 - dioxide - 3 - ylmalonic acid is treated with ethereal diazomethane to give benzyl hydrogen tetrahydrothiophen - 1,1 - dioxide-3-ylmalonate which is then converted to the acid chloride by treatment with thionyl chloride. 4-Tetrahydrothiapyranol is reacted in dry pyridine with benzenesulphonylchloride to give 4-tetrahydrothiapyranyl benzenesulphonate which is reacted with sodiodiethyl malonate to produce diethyl-4-tetrahydrothiopyranyl malonate. The latter is then hydrolysed with ethanolic NaOH to tetrahydrothiapyranyl-4-malonic acid which is converted to its acid chloride by treatment with oxalyl-chloride. Reference has been directed by the Comptroller to Specification 1,004,670.
Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
Compounded solution minus BWC0977 The placebo used during this study is 5% Dextrose for injection. SAD Cohorts: Subjects will receive single infusions of placebo (Compounded solution minus BWC0977) over two hours. MAD Cohorts: Subjects will receive multiple infusions of placebo over 2 hours for 7 or 10 consecutive days.
Background: Understanding the principles and practice of research by health care professionals helps to improve the evidence base for palliative care practice and service delivery. Research is a core competency in palliative care that enables the identification and addressing of problems for patients and their families, establishes best practice and improves ways to manage pain, other symptoms, and concerns. This work was undertaken in the research for all palliative care clinicians (RESPACC) Erasmus+ project. Aim: To identify and develop a set of core research competencies within a structured framework for all members of the multidisciplinary palliative team. Design: A multi-method approach was used including rapid review of literature, Nominal Group Technique, and expert consultation. A quiz to self-assess research competencies outlined within the Framework was produced. Results: The Framework includes 17 competencies organized in 7 domains: The clinical context, Scientific thinking and research design, Ethics and regulatory framework for research, Study and site management, Data management and informatics, Communication and relationships, and Research leadership. In the consultation process 6 of the 17 competencies were considered as required by each individual team member, and 3 to be present within the palliative care team. Conclusion: Using a multi-method approach, the first Palliative Care Research Framework identifying core research competencies for palliative care clinicians has been developed. The aim of the framework was not to transform palliative care clinicians into researchers, but to ensure that clinicians understand the important role of research and its integration into clinical practice.
Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
The invention relates to a pharmaceutical composition containing an unsaturated fatty acid or a derivative thereof, wherein the unsaturated fatty acid is enriched with oxygen, and to an organic solvent. The oxygen enrichment is performed by means of treatment with ozone. The solvent is dimethyl sulfoxide (DMSO). The unsaturated fatty acid is preferably oleic acid. The invention further relates to products containing such a pharmaceutical composition and the use of the pharmaceutical composition, for example as a medical preparation. The pharmaceutical composition has antimicrobial (for example, antibacterial) properties.
It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicifled virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as aT cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant.
Belonging to the technical field of medicine and health, the invention relates to a Chinese medicine decoction, in particular to a method for treating chronic pharyngitis through the combination of a Chinese medicine decoction and ultrasonic atomization. The method makes use of the efficacy of yin nourishing, heat elimination, detoxifcation and pharynx facilitation of the traditional Chinese medicine involved in the decoction prescription. Wherein, balloonflower root and blackberry lily has the functions of heat clearing and detoxification. Honeysuckle flower, forsythia and isatis root can clear heat, detoxify, cooling the blood and benefit the pharynx. Ophiopogogon japonicus and radix scrophulariae can nourish yin and eliminate heat. Muscardine silkworm and periostracum cicadae can reduce phlegm, resolve masses, ventilate the lung and benefit the pharynx. And then, ultrasonic atomization is combined for treatment. The liquid medicine for atomization is prepared with 80000U of gentamycin injection, 5.mg of dexamethasone injection, and the balance normal saline added to make the liquid medicine total 40rnL. The ultrasonic atomization treatment is conducted once a day for 20min, and a course of treatment takes 7d. According to the invention, patients treated by the combination of the Chinese medicine decoction and ultrasonic atomization almost no longer have the symptoms of sore throat, dry sensation, foreign body sensation, cough, hoarseness, etc., and throat mucosa hyperemia disappears. Thus, the method provided in the invention has significant efficacy.
Diclofenac potassium tablets, USP are a benzeneacetic acid derivative. Diclofenac potassium tablets are available for oral administration. Diclofenac potassium, USP is a white to off-white or slightly yellowish crystalline powder and is sparingly soluble in water at 25ºC. The chemical name is Potassium [ o-(2,6-dichloroanilino)phenyl] acetate. The molecular weight is 334.24. Its molecular formula is C 14H 10C1 2KNO 2, and it has the following structural formula: 

The inactive ingredients in diclofenac potassium tablets include: anhydrous lactose, colloidal silicon dioxide, croscarmellose sodium, glyceryl triacetate, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate and titanium dioxide.
Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
The present invention discloses a Chinese medicinal product for protecting the liver and clearing the bowel, which belongs to the Chinese patent medicine range. The Chinese medicinal product is composed of rhizoma polygonati, white peony root, salvia miltiorrhiza, mulberry and aloe in a compounding mode, the components of the Chinese medicinal product are prepared into tablets, oral medicinal liquid or medicinal granules according to a certain proportion by weight and the usual methods for preparing Chinese medicinal tablets, oral medicinal liquid and medicinal granules. After the Chinese medicinal product is eaten for trial by animals receiving trial and constipation patients receiving trial, the defecation times are obviously increased, feces characteristics are softened by 1.14 degrees, the defecation state is improved by 1.10 level, various indexes are all within normal range before and after the Chinese medicinal product is eaten for trial, and the Chinese medicinal product has no obvious influence on bodies. The total effective rate of the Chinese medicinal product is 72%. The present invention has the effect on invigorating yin, promoting the production of the body fluid, activating the blood circulation, relaxing the bowel, being used for the liver, taking the intestine as channels, taking supplementing the liver and emolliating the liver as a main function and taking adding water and lightening hypocatharsis as an auxiliary function. The present invention is rigorously and compactly compounded; the present invention has the advantages of the simultaneous consideration of the internal and the external and the simultaneous application of taking a temporary solution and effecting a permanent cure, and therefore, the present invention has a function of relaxing the bowel and a function of the adjuvant therapy of chemical liver injury. The present invention is really a medicine and food benefit preparation which is taken for a long time and often used.
A Randomized Clinical Trial was taken Fatima Jinnah Dental College Hospital, Karachi, from 1st November 2019 To 30th April 2020. Total 30 teeth in each group were included. Preoperatively shade was checked. The mixture was applied 10 times or more during the same session. Total treatment time was around 30 minutes. Every patient received entire microabrasion treatment. At the end of the treatment, neutral sodium fluoride gel was applied. Then changes in shade were checked. Descriptive statistics were calculated.